Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

用于治疗传染病的治疗剂的合成

• 批准号: 10352180
• 负责人: MARK MIDDLETON
• 金额: $ 125.65万
• 依托单位: STARKS ASSOCIATES, INC.
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-16 至 2022-02-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10352180
• 关键词: Acquired Immunodeficiency Syndrome; Animals; Chemicals; Clinical Research; Communicable Diseases; Contractor; Contracts; Diagnosis; Diagnostic; Disease; HIV; Immune; Immunology; In Vitro; Local Microbicides; Mediating; Medical; Microbiology; National Institute of Allergy and Infectious Disease; Phase; Prevention; Regulation; Research; Research Support; Resources; Testing; Therapeutic; Therapeutic Agents; United States Dept. of Health and Human Services; United States National Institutes of Health; infectious disease treatment; microbicide; vaccine development

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID Division of AIDS has a requirement for the synthesis of therapeutics directed against HIV and other infectious diseases as well as agents to serve and anti-HIV topical microbicides. This initiative provides the resources for the synthesis of microbicides and compounds for the treatment of HIV, and other infectious diseases of relevance to the research agenda of NIAID. The contract will synthesize chemicals, in compliance with FDA’s current Good Manufacturing Practice (cGMP) regulations if necessary, in quantities needed for testing in in vitro screens, animals, or early Phase I clinical studies.

美国国家过敏和传染病研究所 (NIAID)、美国国立卫生研究院 (NIH) 和美国卫生与公众服务部 (DHHS) 支持与微生物学和免疫学基本了解相关的研究，从而促进疫苗、疗法的开发以及用于预防、治疗和诊断传染病和免疫介导疾病的医学诊断 NIAID 艾滋病部门需要合成针对 HIV 和其他传染病的治疗方法以及服务和试剂。该计划为治疗 HIV 以及与 NIAID 研究议程相关的其他传染病的杀微生物剂和化合物的合成提供了资源，该合同将按照 FDA 现行的良好生产规范合成化学品。如果有必要的话，按照体外筛选、动物或早期 I 期临床研究测试所需的数量进行实践 (cGMP)。